Somatic tumor mutations detected by targeted next generation sequencing in minute amounts of serum-derived cell-free DNA

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Weerts, Marjolein J A ^a   Van Marion, Ronald ^a   Helmijr, Jean C A ^a   Beaufort, Corine M ^a   Krol, Niels M G ^a,b   Trapman Jansen, Anita M A C ^a   Dinjens, Winand N M ^a   Sleijfer, Stefan ^a   Jansen, Maurice P H M ^a   Martens, John W M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE NUCLEIC ACID; DNA;

BLOOD; BREAST TUMOR; DNA SEQUENCE; FEMALE; GENETICS; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; METASTASIS; PATHOLOGY; PROCEDURES;

BREAST NEOPLASMS; CELL-FREE NUCLEIC ACIDS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM METASTASIS; SEQUENCE ANALYSIS, DNA;

EID: 85019916718     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02388-7     Document Type: Article

References (37)

1. Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775, 181-232 (2007).
2. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
3. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6, 224ra224 (2014).
4. Jiang, C. & Zhao, Z. Mutational spectrum in the recent human genome inferred by single nucleotide polymorphisms. Genomics 88, 527-534 (2006).
5. Hiltemann, S., Jenster, G., Trapman, J., van der Spek, P. & Stubbs, A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res 25, 1382-1390 (2015).
6. Forbes, S. A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43, D805-811 (2015).
7. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44, D862-868 (2016).
8. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29, 308-311 (2001).
9. (ESP), N. G. E. S. P. Exome Variant Server, http://evs.gs.washington.edu/EVS/.
10. Genomes Project, C. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
11. Genome of the Netherlands, C. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet 46, 818-825 (2014).
12. O'Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res 44, D733-745 (2016).
13. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
14. Do, H. & Dobrovic, A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget 3, 546-558 (2012).
15. Do, H., Wong, S. Q., Li, J. & Dobrovic, A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem 59, 1376-1383 (2013).
16. Kerick, M. et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 4, 68 (2011).
17. Wong, S. Q. et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics 7, 23 (2014).
18. Bourgon, R. et al. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res 20, 2080-2091 (2014).
19. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
20. Tiersch, T. R., Chandler, R. W., Wachtel, S. S. & Elias, S. Reference standards for flow cytometry and application in comparative studies of nuclear DNA content. Cytometry 10, 706-710 (1989).
21. Kanagawa, T. Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng 96, 317-323 (2003).
22. Canzoniero, J. V. & Park, B. H. Use of cell free DNA in breast oncology. Biochim Biophys Acta 1865, 266-274 (2016).
23. Chan, K. C., Yeung, S. W., Lui, W. B., Rainer, T. H. & Lo, Y. M. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 51, 781-784 (2005).
24. Wong, F. C. et al. Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clin Biochem 49, 1379-1386 (2016).
25. Parpart-Li, S. et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res (2016).
26. Medina Diaz, I. et al. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One 11, e0166354 (2016).
27. van Dessel, L. F. et al. Application of circulating tumor DNA in prospective clinical oncology trials: standardization of pre-analytical conditions. Mol Oncol (2017).
28. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199-1209 (2013).
29. Parsons, H. A. et al. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23, 379-386 (2017).
30. Shaw, J. A. et al. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res 23, 88-96 (2017).
31. Page, K. et al. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. Clin Chem 63, 532-541 (2017).
32. Rothe, F. et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25, 1959-1965 (2014).
33. van Lier, M. G. et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 14, 181-197 (2010).
34. Berns, E. M. et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52, 1107-1113 (1992).
35. Jansen, M. P. et al. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget 7, 43412-43418 (2016).
36. Andrews, S. FastQC A Quality Control tool for High Throughput Sequence Data, http://www.bioinformatics.babraham.ac.uk/projects/fastqc (6-6-14).
37. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010).